Invitation to press and analyst briefing on the Year-End Report

Invitation to press and analyst briefing on the Year-End Report

Wednesday, February 13, 10:00 a.m, (CET) at Operaterrassen, Stockholm.

Bengt Ågerup, CEO will present the company and comment on the report.

Moderator: Martin Sikorski, Cheuvreux.

To participate, please register in one of the following ways: at
www.financialhearings.com, or mail hearings@financialhearings.com or by phone +
46(0) 8 411 43 80. 

Wednesday's presentation can also be followed live by telephone conference,
which is accessible by dialling + 44 (0) 20 8817 9301, confirmation code: 155
3458 or Web Cast Live at. www.financialhearings.com or www.q-med.com. The slide
presentation will be available at www.q-med.com, on Wednesday, February 13 at
the latest 10.00 a.m.

Q-Med's year-end report will be published around 08:00 a.m Wednesday, February
13.

Financial information from Q-Med during Year 2008:

29  April	 Interim Report January - March 2008
29  April Annual General Meeting
24  July  Interim Report January - June 2008
24  October Interim Report January - September 2008






Queries should be addressed to:
Madelene Sandgren, Director Investor Relations and Corporate Communications 
Tel: +46 (0) 70 974 9015 

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux™ for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, Zuidex™ for the treatment of stress urinary
incontinence in women, and Solesta™ for the treatment of fecal incontinence.
Sales are made through the company's own subsidiaries or distributors in over 70
countries. Q Med today has just over 700 coworkers, with close to 500 at the
company's head office and production facility in Uppsala, Sweden. Q-Med AB is
listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.